课题基金 / 基金详情

Core--Antibody

Core--Antibody
核心--抗体
批准号:
6657065
负责人:
Lisa A Cavacini
金额:
$6.8万
依托单位国家:
美国
项目类别:
财政年份:
2002
资助国家:
美国
项目状态:
已结题
起止时间:
2002-09-01 至 2003-08-31

项目摘要

项目成果

Lisa A Cavacini的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The antibody core will generate monoclonal antibodies (Mabs) for the study of oral pathogenesis of gammaherpesvirus infections. Monoclonal antibodies will be generated to be used to (1) characterize viral antigens and (2) to study the immune response to known viral antigens. For project 1, Mabs will be generated to rhesus lymphocryptovirus (LCV) gene products to study latent and lytic infection. Additionally, we proposed in later years of the project, to correlate the acute rhesus macaque response to LCV with the antibody repertoire of individuals with nasopharyngeal carcinoma (NPC). Mabs will be generated to RRV (project 2) to study Kaposi's sarcoma-associated herpesvirus (KSHV) proteins and will be used in immunohistochemistry to study KSHV gene expression in the oral cavity (Project 3). Human-Mabs, produced from the B cells of individuals infected with KSHV. The development of human monoclonal antibodies and the study of antibody responses have been a long-standing focus of the laboratory. We have numerous collaborations with others in the field of virology, microbiology and oncology to study antibody responses to natural infections/diseases vaccines and cancer. The combination of this experience and the availability of efficient fusion partners will contribute to the success of this core.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy
Structure-guided and epitope-based design of potent and broadly neutralizing nanobodies for COVID-19 mucosal immunotherapy
Mechanism of Potent Neutralization of HIV by IgA CD4i Antibody
海外基金